About: Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
Creator	Du, Lanying Jiang, Shibo Lustigman, Sara Zhan, Bin Tseng, Chien-Te Curti, Elena Jones, Kathryn Hotez, Peter Bottazzi, Maria
Source	Medline; PMC
abstract	A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.
has issue date	2012-12-01(xsd:dateTime)
bibo:doi	10.1586/erv.12.126
bibo:pmid	23252385
has license	bronze-oa
sha1sum (hex)	a6ad701ec0c2ef70b398f81f4656332ed78addf2
schema:url	https://doi.org/10.1586/erv.12.126
resource representing a document's title	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
has PubMed Central identifier	PMC3586247
has PubMed identifier	23252385
schema:publication	Expert Review of Vaccines
resource representing a document's body	covid:a6ad701ec0c2ef70b398f81f4656332ed78addf2#body_text
is schema:about of	named entity 'RECOMBINANT' named entity 'Children' named entity 'Center' named entity 'protein' named entity 'Development' named entity 'severe acute respiratory syndrome' named entity 'VACCINE' named entity 'BEING' named entity 'PARTNER' named entity 'VACCINE DEVELOPMENT' named entity 'HOSPITAL' named entity 'TEXAS' named entity 'TO PREVENT' named entity 'CORPORATION' named entity 'CLASSIFIED' named entity 'BINDING' named entity 'RECEPTOR' named entity 'VACCINE' named entity 'UNIVERSITY' named entity 'MANUFACTURE' named entity 'IMMUNOPATHOLOGY' named entity 'CAUSED BY' named entity 'SYNTHETIC' named entity 'RESEARCH' named entity 'INSTITUTE' named entity 'RECOMBINANT' named entity 'NIH' named entity 'MEDICAL' named entity 'ARMY' named entity 'INDUCE' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'PATHOGEN' named entity 'YEARS' named entity 'NEW YORK BLOOD CENTER' named entity 'S PROTEIN' named entity 'SUBUNIT VACCINE' named entity 'INDUSTRIAL' named entity '27S' named entity '28S' named entity 'COLLABORATION' named entity 'PARTNERSHIP' named entity 'REED' named entity 'CENTER' named entity 'ACADEMIC' named entity 'SPIKE' named entity 'RBD' named entity 'CHILDREN' named entity 'DESIGN' named entity 'SABIN VACCINE' named entity 'PUBLIC' named entity 'PROTEIN RECEPTOR' named entity 'BINDING' named entity 'DOMAIN' named entity 'NIH' named entity 'CORONAVIRUS' named entity 'ACCESS' named entity 'PROTEIN ' named entity 'DOMAIN' named entity 'ALUM' named entity 'CATEGORY' named entity 'NONPROFIT' named entity 'NEUTRALIZING ANTIBODIES' named entity 'BRANCH' named entity 'LED' named entity 'PRODUCT DEVELOPMENT' named entity 'GOAL' named entity 'SARS CORONAVIRUS' named entity 'CAUSING' named entity 'SARS VACCINE' named entity 'CLINICAL TESTING' named entity 'LIPID A' named entity 'DEVELOPMENT' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software